Genmab — Marts 2011
-
lidt transition i staffing
-
lidt retention bonus men ikke material
-
20-40 mdkk er lundbeck og reimbursement of cost
-
very little fra gsk
-
EGFR omkostninger er forsøg
-
very little i prepwork
-
så meget er forpligtet i forsøg
-
så de trimmer måske ved at lukke forsøg
-
TenX, er default, vil vi se data fra phase 3
-
og så lidt om skat
-
og roche milestones?
-
Forsøgene kører stadigt, data kommer
-
så data kommer, men det er svært at forudsige
-
ingen milestones fra roche er inkluderet
-
skat er lidt høj...20 mill og begrundelsen er warrant
-
så det er lisa der koster 20 mill i skatten
-
så den falder igen til 14-15 i 2011
-
eller 5 mill
-
cd38....
-
what level of efficasy kigger de efter
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind